argenx reports Q3 2026 VYVGART sales of $1.7 billion, outlines pipeline timelines
The company said it is preparing a year-end IMNM filing for VYVGART Hytrulo and expects Phase 3 MMN data for empasiprubart in December 2026.
argenx SE said it generated $1.7 billion in global product net sales in the third quarter of 2026, representing 54% year-over-year growth and 13% quarter-over-quarter growth1. The company also submitted a supplemental Biologics License Application for VYVGART in ocular myasthenia gravis to the FDA, and the agency accepted for priority review the sBLA for VYVGART and VYVGART Hytrulo in pediatric gMG, setting a PDUFA target action date of February 20271.
On the pipeline, argenx said its VYVGART Hytrulo autoinjector is expected to launch in the second half of 2027 for all approved indications1. The company reported results from a late-stage study called "ALKIVIA," saying it observed consistent and clinically meaningful treatment effects across immune-mediated necrotizing myopathy and dermatomyositis, and that the sBLA for VYVGART Hytrulo in IMNM remains on track for submission by year-end 2026, supported by Breakthrough Therapy Designation, with an additional registrational study planned in DM1.
Other near-term catalysts cited include topline Phase 3 EMPASSION results in multifocal motor neuropathy expected in December 2026, and topline Phase 3 EMVIGORATE and EMNERGIZE results in CIDP anticipated in the second half of 20271. Separately, the company said it is moving FB102 into Phase 3 for celiac disease after seeing favorable Phase 2 data, while continuing programs in alopecia areata and vitiligo and exploring use in other autoimmune conditions1.
On finances, argenx reported $2.6 billion in cash and cash equivalents and $1.1 billion in current financial assets, totaling $3.7 billion as of September 30, 2026, down from $4.4 billion at the end of 20251, a decline the company attributed to paying roughly $2.1 billion, net of acquired cash, for its acquisition of Forte Biosciences Inc. For the full year, argenx said combined R&D and SG&A expenses are now expected to be approximately $4 billion for 2026, including Forte transaction-related costs1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.